Kulicke and Soffa signals 15% sequential revenue growth for Q2 2026 while advancing advanced packaging and memory opportunities
INmune Bio Inc. Common stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $1.39
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS